A business plan to help the 'global south' in its fight against neglected diseases

Health Affairs

Volumn 28, Issue 6, 2009, Pages 1760-1773

  Frew, Sarah E ^a   Liu, Victor Y ^b   Singer, Peter A ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; SHANCHOL; UNCLASSIFIED DRUG;

BIOTECHNOLOGY; CHOLERA; COMMERCIAL PHENOMENA; CONFERENCE PAPER; DRUG COST; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; HEALTH ECONOMICS; HUMAN; NON PROFIT ORGANIZATION; TROPICAL DISEASE;

BIOTECHNOLOGY; COMMERCE; COMMUNICABLE DISEASE CONTROL; HUMANS; NEGLECTED DISEASES; ORGANIZATIONAL OBJECTIVES; PLANNING TECHNIQUES; WORLD HEALTH;

EID: 77952148001     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.28.6.1760     Document Type: Conference Paper

References (21)

1. Department of Control of Neglected Tropical Diseases. Neglected tropical diseases, hidden successes, emerging opportunities [Internet]. Geneva (Switzerland): World Heakh Organization; 2006 [cited 2009 May 12]. Available from htçy/whqlibdoc.who.int/hq/2006/WHO-CDS-NTD-2006.2-eng.pdf
2. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD, et aL Control of neglected tropical diseases. N Engl J Med. 2007;357(10):1018-27.
3. Widdus R, White K. Combating diseases associated with poverty: financing strategies for product development and the potential role of public-private partnerships [Internet]. Geneva (Switzerland): Initiative on Public-Private Partnerships for Health; 2004 Aug [cited 2009 Sep 15]. Available from http/www.globaforumhealth.org/content/download/394/2322/file/s14800e.pdf
4. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 2002;359(9324):2188-94.
5. Chirac P, Torreele E. Global framework on essential health R&D. Lancet. 2006;367(9522):1560-1.
6. Trouiller P, Torreele E, Olliaro P, White N, Foster S, Wirth D, et aL Drugs for neglected diseases: a failure of the market and a public health failure? Trop Med Int Health. 2001;6(11):945-51.
7. Morel CM, Acharya T, Broun D, Dangi A, Elias C, Ganguly NK, et aL Health innovation networks to help developing countries address neglected diseases. Science. 2005;309(5733):401-4.
8. Moran M. A breakthrough in R&D for neglected diseases: a new way to get the drugs we need PLoS Med. 2005;2(9):e302.
9. Moran M, Guzman J, Ropars AL, McDonald A, Sturm T, Jameson N, et aL Neglected disease research and development, how much are we really spending? [Internet]. London (U.K.): George Institute; 2008 [cited 2009 Sep 15]. Available from httpy/www.thegeorgeinstitute.org/shadomx/apps/fms/fmsdownload.cfm?file- uuid=409DlEFD-BF15-8C94-E71C-288DE35DD0B2&siteName=iih
10. Global Network for Neglected Tropical Diseases. Disease-specific achievements [Internet]. Washington (DC): Global Network; [updated 2009 Jun 29; cited 2009 Jun 16]. Available from httpV/www.globalnetwork.oiwhat-we-do/success- stories/disease-specific-achievements
11. Thylofors B, Alleman M. Towards the elimination of onchocerciasis. Ann Trop Med Parasitol. 2006;100(8): 733-46.
12. Al-Bader S, Frew SE, Essajee I, Liu VY, Daar AS, Singer PA. Small but tenacious: South Africa's health biotech sector. Nat BiotechnoL 2009;27(5):427-45.
13. Frew SE, Rezaie R, Sammut SM, Ray M, Daar AS, Singer PA. India's health biotech sector at a crossroads. Nat BiotechnoL 2007;25(4):403-17.
14. Frew SE, Sammut SM, Shore AF, Ramjist JK, Al-Bader S, Rezaie R, et aL Chinese health biotech and the billion-patient market. Nat BiotechnoL 2008;26(1):37-53.
15. Rezaie R, Frew SE, Sammut SM, Maliakkal MR, Daar AS, Singer PA. Brazilian health biotech - fostering crosstalk between public and private sectors, ure Biotechnol. 2008;26(6):627-44.
16. Supplemental Exhibits 1 and 2 provide more detail on these developments; they are available online at httpy/contmt.healthaffairs.org/cgi/content/full/28/ 6A760/DCl.
17. Shanghai United Biotech. OraVacs [Internet]. Shanghai (China): Shanghai United Biotech; [updated 2009; cited 2009 Jun 21]. Available from nttpy/e.unitedbioteckcom.cn/en/BnProduct-OCV-general.asp
18. World Heakh Organizatioa World Heakh Organization Global Health Atlas [Internet]. Geneva (Switzerland); WHO; [updated 2007; cited 2009 Aug 9]. Available from: http://apps.who.int/globalatlas/dataQuery/default.asp
19. Frew SE, Kettler HE, Singer PA. The Indian and Chinese heakh biotechnology industries: potential champions of global health? Health Aff (Millwood). 2008;27(4):1029-41.
20. Boston Consulting Group. Making a difference - BCG and its pro bono clients [Internet]. Boston (MA); BCG; 2004 [cited 2009 Sep 21]. Available from ht?://www.bcg.com/documents/file14459.pdf
21. Gates B. 2007 Harvard commencement: Bill Gates [Internet]. Seattle (WA): Bill & Melinda Gates Foundation; [updated 2007 Jun 6; cited 2009 Jun 16]. Available from http://www.gatesfoundation.org/speeches-commentary/Pages/bill- gates-2W7-harvard-commencement.aspx